About PolyVascular
PolyVascular is a Healthcare company based in Houston (United States) founded in 2014. It operates as a polymeric transcatheter valves are developed for congenital heart disease treatment. PolyVascular has raised $795 thousand across 5 funding rounds from investors including HHS, SBIR and CobiCure MedTech. Its chief executive is Tim Smokoff. PolyVascular offers products and services including Transcatheter Pulmonary Valve and Delivery System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is PolyVascular, Inc. Its competitors include Shockwave Medical, Venus MedTech, Cardiac Dimensions, Pi-Cardia and Peijia Medical Technologies and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
PolyVascular was founded in 2014 in Houston, United States, within the medical device sector. Focus is placed on polymeric transcatheter valves designed for children with congenital heart disease. The transcatheter pulmonary valve is employed in minimally invasive procedures, which extend intervals between necessary open-heart surgeries. Operations center on innovation in pediatric cardiology solutions.
- Headquarters Houston, United States
- SectorsHealthcare
- Email••••••••
- Website polyvascular.com
- Social LinkedIn X
- Legal Name Polyvascular, Inc.
- Total Equity Funding$795K (USD)
in 5 rounds
- Latest Funding Round$2M (USD), Grant
Aug 2023
- InvestorsHHS
& 2 more
Products & Services of PolyVascular
PolyVascular offers a comprehensive portfolio of products and services, including Transcatheter Pulmonary Valve and Delivery System.
Polymer-based valve for minimally invasive treatment of congenital heart defects
System for safe percutaneous positioning of heart valves in children
Funding Insights of PolyVascular
PolyVascular has successfully raised a total of $795K across 5 strategic funding rounds. The most recent funding activity was a Grant round of $2 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $795,000
- Total Rounds 5
- Last Round Grant — $2M
- First Round $2.58M
(Aug 2016)
- Investors Count 3
All 5 funding rounds of PolyVascular with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $2M | Grant | – | – | |
| Jul 2023 | $795,000 | Seed | – | – | – |
| Mar 2021 | $2M | Grant | – | – | |
| Mar 2018 | – | Seed | – | – | – |
| Aug 2016 | $2.58M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in PolyVascular
PolyVascular has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, SBIR and CobiCure MedTech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CobiCure MedTech is focused on pediatric medical device development. | 2022 | cobicuremedtech.org | New York, United States | |
Federal innovation and scientific achievement services are provided. | 1982 | sbir.gov | Lithia Springs, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for PolyVascular
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PolyVascular
4 people are tracked at PolyVascular (4 in leadership).
| Name | Role | Group |
|---|---|---|
Tim Smokoff | CEO | Leadership |
Tim Moran | CEO | Leadership |
Cindy Clague | VP Of R&d | Leadership |
Mary Bales | Vp, Investor Relations | Leadership |
Complete people profiles for PolyVascular
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PolyVascular
3 dated milestones of PolyVascular across 9 years, from founding to its latest funding, stage changes and deals.
- Founded PolyVascular is founded.
- Funding First funding round of $2.6M.
- Funding Latest funding round, Grant, of $2.0M.
Competitors of PolyVascular
PolyVascular has 10 listed competitors in our database, 10 of them funded. They include Shockwave Medical, Venus MedTech, Cardiac Dimensions, Pi-Cardia and Peijia Medical Technologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| shockwavemedical.com | 2009 | Santa Clara, United States | $147.5M | 1,394 | Cardiovascular balloon dilation catheters with lithotripsy electrodes are developed. | |
| venusmedtech.com | 2009 | Hangzhou, China | $37M | – | Transcatheter aortic and pulmonic valves are developed for cardiovascular procedures. | |
| cardiacdimensions.com | 2001 | Kirkland, United States | $260.8M | 31 | Invasive cardiac implants for heart failure treatment are developed. | |
| pi-cardia.net | 2009 | Rehovot, Israel | $40M | – | Non-implant devices for cardiac valve repair are developed and manufactured. | |
| peijiamedical.com | 2012 | Suzhou, China | $110.08M | – | Medical devices for cardiac and cerebrovascular treatments are developed. | |
| cardioflowmedtech.com | 2015 | Pudong, China | $132.02M | – | Smart medical devices for heart valve diseases are developed. | |
| pecalabs.com | 2011 | Pittsburgh, United States | $19.91M | – | Pediatric cardiac surgical devices are developed for congenital heart defects. | |
| tricares.com | 2013 | Aschheim, Germany | $102.84M | – | Minimally invasive tricuspid valve replacement system is developed. | |
| jenavalve.com | 2006 | Irvine, United States | $363.7M | 198 | Pericardial transcatheter aortic valve replacement systems are provided. | |
| capstanmedical.com | 2020 | Santa Cruz, United States | $141.4M | – | Medical devices for structural heart disease treatment are developed. |
Detailed competitors of PolyVascular
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pediatrics
10 companies that operate in the same segment as PolyVascular (Pediatrics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Owlet is recognized for developing FDA-cleared smart baby monitors. | 2013 | Lehi, Utah, United States | USD 54.96 M | USD 105.71 M | 85 | |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Smart baby monitors and sleep tracking solutions are provided. | 2014 | New York, New York, United States | USD 116.6 M | – | – | |
Provider of diagnostic products for pediatrics | 2013 | Durham, North Carolina, United States | USD 95.89 M | – | – | |
Eye-tracking solutions for vision assessment and treatment are provided. | 2016 | Lod, Central District, Israel | USD 8 M | – | – | |
Patient vital signs are monitored via wearable devices and software. | 2018 | Niles, Illinois, United States | USD 71 M | – | – | |
Pediatric orthopedic devices are developed for surgical applications. | 2006 | Warsaw, United States | USD 51.55 M | USD 236.35 M | 562 | |
Gene therapy platform for rare disease treatments is developed. | 2018 | Exton, Pennsylvania, United States | USD 192.8 M | – | 41 | |
Pediatric cardiac surgical devices are developed for congenital heart defects. | 2011 | Pittsburgh, Pennsylvania, United States | USD 22.56 M | – | – | |
Drug-delivery platforms for pediatric wart treatments are developed. | 2020 | San Antonio, Texas, United States | USD 262.71 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Polyvascular
Complete news archive for PolyVascular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PolyVascular
PolyVascular was founded in 2014 and raised its 1st funding round 2 years after it was founded.
PolyVascular is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Tim Smokoff is the current CEO of PolyVascular.
PolyVascular is a funded company, having raised a total of $795K across 5 funding rounds to date. The company's 1st funding round was a Grant of $2.58M, raised on Aug 2016.
PolyVascular was founded in 2014 in Houston, United States, within the medical device sector. Focus is placed on polymeric transcatheter valves designed for children with congenital heart disease. The transcatheter pulmonary valve is employed in minimally invasive procedures, which extend intervals between necessary open-heart surgeries. Operations center on innovation in pediatric cardiology solutions.
PolyVascular's top competitors include Shockwave Medical, Cardiac Dimensions and JenaValve Technology.
PolyVascular offers Transcatheter Pulmonary Valve and Delivery System.
PolyVascular has 3 investors. Key investors include HHS, SBIR, and CobiCure MedTech.
PolyVascular operates through Polyvascular, Inc..